Reduced expression of P120 catenin in cholangiocarcinoma correlated with tumor clinicopathologic parameters

World Journal of Gastroenterology

Volumn 14, Issue 23, 2008, Pages 3739-3744

  Zhai, Bo ^a   Yan, He Xin ^a   Liu, Shu Qin ^a   Chen, Lei ^a   Wu, Meng Chao ^a   Wang, Hong Yang ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Clinicopathologic feature; Intrahepatic choloangiocarcinoma; Invasion and metastasis; P120; Survival

Indexed keywords

CATENIN; P120 CATENIN; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER SURVIVAL; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DISEASE MARKER; DOWN REGULATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; ONCOLOGICAL PARAMETERS; PROGNOSIS; PROTEIN EXPRESSION;

EID: 54349083598     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.3739     Document Type: Article

References (29)

1. Reynolds AB, Herbert L, Cleveland JL, Berg ST, Gaut JR. p120, a novel substrate of protein tyrosine kinase receptors and of p60v-src, is related to cadherin-binding factors beta-catenin, plakoglobin and armadillo. Oncogene 1992; 7: 2439-2445
2. Yanagisawa M, Anastasiadis PZ. p120 catenin is essential for mesenchymal cadherin-mediated regulation of cell motility and invasiveness. J Cell Biol 2006; 174: 1087-1096
3. Nollet F, Berx G, van Roy F. The role of the E-cadherin/catenin adhesion complex in the development and progression of cancer. Mol Cell Biol Res Commun 1999; 2: 77-85
4. Xiao K, Oas RG, Chiasson CM, Kowalczyk AP. Role of p120-catenin in cadherin trafficking. Biochim Biophys Acta 2007; 1773: 8-16
5. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001; 33: 1353-1357
6. The general rules for the clinical and pathological study of primary liver cancer. Liver Cancer Study Group of Japan. Jpn J Surg 1989; 19: 98-129
7. Hermanek P, Hutter RVP, Sobin LH. TNM Atlas, UICC. 4th ed. Berlin: Springer 1997: 115-123
8. Gamallo C, Palacios J, Suarez A, Pizarro A, Navarro P, Quintanilla M, Cano A. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am J Pathol 1993; 142: 987-993
9. Ashida K, Terada T, Kitamura Y, Kaibara N. Expression of E-cadherin, alpha-catenin, beta-catenin, and CD44 (standard and variant isoforms) in human cholangiocarcinoma: an immunohistochemical study. Hepatology 1998; 27: 974-982
10. Sato K, Murai H, Ueda Y, Katsuda S. Intrahepatic sarcomatoid cholangiocarcinoma of round cell variant: a case report and immunohistochemical studies. Virchows Arch 2006; 449: 585-590
11. Settakorn J, Kaewpila N, Burns GF, Leong AS, FAT, E-cadherin, beta catenin, HER 2/neu, Ki67 immunoexpression, and histological grade in intrahepatic cholangiocarcinoma. J Clin Pathol 2005; 58: 1249-1254
12. Tokumoto N, Ikeda S, Ishizaki Y, Kurihara T, Ozaki S, Iseki M, Shimizu Y, Itamoto T, Arihiro K, Okajima M, Asahara T. Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas. Int J Oncol 2005; 27: 973-980
13. Asayama Y, Taguchi Ki K, Aishima Si S, Nishi H, Masuda K, Tsuneyoshi M. The mode of tumour progression in combined hepatocellular carcinoma and cholangiocarcinoma: an immunohistochemical analysis of E-cadherin, alpha-catenin and beta-catenin. Liver 2002; 22: 43-50
14. Sugimachi K, Taguchi K, Aishima S, Tanaka S, Shimada M, Kajiyama K, Sugimachi K, Tsuneyoshi M. Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma. Mod Pathol 2001; 14: 900-905
15. Thoreson MA, Reynolds AB. Altered expression of the catenin p120 in human cancer: implications for tumor progression. Differentiation 2002; 70: 583-589
16. Reynolds AB, Carnahan RH. Regulation of cadherin stability and turnover by p120ctn: implications in disease and cancer. Semin Cell Dev Biol 2004; 15: 657-663
17. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, Bemis L, Gemmill RM, Drabkin HA, Franklin WA. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol 2002; 20: 2417-2428
18. Sarrio D, Perez-Mies B, Hardisson D, Moreno-Bueno G, Suarez A, Cano A, Martin-Perez J, Gamallo C, Palacios J. Cytoplasmic localization of p120ctn and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. Oncogene 2004; 23: 3272-3283
19. Ishizaki Y, Omori Y, Momiyama M, Nishikawa Y, Tokairin T, Manabe M, Enomoto K. Reduced expression and aberrant localization of p120catenin in human squamous cell carcinoma of the skin. J Dermatol Sci 2004; 34: 99-108
20. Qian ZR, Sano T, Yoshimoto K, Asa SL, Yamada S, Mizusawa N, Kudo E. Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. Mod Pathol 2007; 20: 1269-1277
21. Bremnes RM, Veve R, Gabrielson E, Hirsch FR, Baron A, Bemis L, Gemmill RM, Drabkin HA, Franklin WA. High-throughput tissue microarray analysis used to evaluate biology and prognostic significance of the E-cadherin pathway in non-small-cell lung cancer. J Clin Oncol 2002; 20: 2417-2428
22. Roczniak-Ferguson A, Reynolds AB. Regulation of p120-catenin nucleocytoplasmic shuttling activity. J Cell Sci 2003; 116: 4201-4212
23. Mayerle J, Friess H, Buchler MW, Schnekenburger J, Weiss FU, Zimmer KP, Domschke W, Lerch MM. Up-regulation, nuclear import, and tumor growth stimulation of the adhesion protein p120 in pancreatic cancer. Gastroenterology 2003; 124: 949-960
24. Osada T, Sakamoto M, Ino Y, Iwamatsu A, Matsuno Y, Muto T, Hirohashi S. E-cadherin is involved in the intrahepatic metastasis of hepatocellular carcinoma. Hepatology 1996; 24: 1460-1467
25. Bellovin DI, Bates RC, Muzikansky A, Rimm DL, Mercurio AM. Altered localization of p120 catenin during epithelial to mesenchymal transition of colon carcinoma is prognostic for aggressive disease. Cancer Res 2005; 65: 10938-10945
26. Wang EH, Liu Y, Xu HT, Dai SD, Liu N, Xie CY, Yuan XM. Abnormal expression and clinicopathologic significance of p120-catenin in lung cancer. Histol Histopathol 2006; 21: 841-847
27. Wijnhoven BP, Pignatelli M, Dinjens WN, Tilanus HW. Reduced p120ctn expression correlates with poor survival in patients with adenocarcinoma of the gastroesophageal junction. J Surg Oncol 2005; 92: 116-123
28. Bantis A, Giannopoulos A, Gonidi M, Liossi A, Aggelonidou E, Petrakakou E, Athanassiades P, Athanassiadou P. Expression of p120, Ki-67 and PCNA as proliferation biomarkers in imprint smears of prostate carcinoma and their prognostic value. Cytopathology 2004; 15: 25-31
29. Nakopoulou L, Gakiopoulou-Givalou H, Karayiannakis AJ, Giannopoulou I, Keramopoulos A, Davaris P, Pignatelli M. Abnormal alpha-catenin expression in invasive breast cancer correlates with poor patient survival. Histopathology 2002; 40: 536-546